Breast Cancer Clinical Trials in Baltimore

Showing 201-220 of 805 trials

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer+7 more

Volastra Therapeutics, Inc.200 participantsStarted Oct 2023

Los Angeles, California, United States • Newport Beach, California, United States • Aurora, Colorado, United States +11 more locations

Active Not RecruitingPhase 1< 1 mile

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more

Nanobiotix145 participantsStarted Jan 2019

San Francisco, California, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +10 more locations

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Breast Cancer Trials in Other Cities

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

CARE (Chemotherapy Alopecia REduction)

National Mammography Database

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Other Conditions in Baltimore